no treatment added-Forest Laboratories-fibromyalgia

The designation "no treatment added-Forest Laboratories-fibromyalgia" refers to the control arm of a Phase 3 clinical trial (NCT00907127) conducted by Forest Laboratories. This study was designed to evaluate the safety and efficacy of adding milnacipran to an existing pregabalin regimen in patients with fibromyalgia who had achieved an incomplete response to pregabalin monotherapy (300 or 450 mg/day). In this specific arm, patients continued their current dose of pregabalin without the addition of any other therapeutic agent. The active pharmacological component in this arm is pregabalin, a small molecule ligand that binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system. This binding modulates the release of several excitatory neurotransmitters, including glutamate, norepinephrine, and substance P, thereby providing analgesic and anxiolytic effects relevant to the management of fibromyalgia symptoms.